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ABSTRACT
Introduction: Hypercholesterolemia has been proven as a main pathogenic trigger for pathogenesis of atherosclero-
sis. Atherosclerosis characterised by chronic inflammatory process and increased expression of inflammatory mark-
ers. In this study; Trihoney (a combination of three types of natural honey namely: Trigona, mellifera, and Dorsata) 
was investigated for its anti-inflammatory effect in hypercholesterolemic atherosclerotic rabbits. Methods: Thirty 
male New Zealand white rabbits (NZW) were grouped into: normal diet (C), normal diet with 0.6g/kg/day of Tri-
honey (C+H), 1% cholesterol diet (HCD), 1% cholesterol diet with 0.6g/kg/day of Trihoney (HCD+H), and 1% 
cholesterol diet with 2mg/kg/day of atorvastatin (HCD+At.). After 12 weeks of starting the experiment, animals were 
sacrificed and serum analysed for homocysteine and pro-atherogenic inflammatory markers such as: interleukin-1β 
(IL-1β), interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-α). Fasting serum glucose was analysed to assess gly-
caemic status. Results: Trihoney treated group showed significantly lower (p<0.05) serum IL-1β and IL-6 compared to 
the HCD group. Trihoney supplementation resulted in significant (p<0.001) reduction of serum TNF-α compared to 
HCD group. Experimental group HCD had serum homocysteine level comparable to that of the control groups with-
out any significant difference despite little increase in the mean value. Trihoney treated group had serum homocys-
teine comparable to the controls. All experimental groups showed fasting serum glucose comparable to the control. 
Conclusion:  This study showed that Trihoney has an anti-inflammatory function and may be used as an adjuvant to 
statins for management of atherosclerotic cardiovascular diseases even in diabetic subjects.  
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INTRODUCTION
Atherosclerosis is characterised by chronic inflammatory 
process and increased expression of inflammatory 
markers (1).  Inflammatory markers implicated in the 
pathogenesis of atherosclerosis are the pro-atherogenic 
cytokines (IL-1β, IL-6, TNF-α) (2), in addition to 
adhesion molecules such as: ICAM-1 and VCAM-1 
which together with those cytokines play an important 
role in atherosclerotic plaque formation, and found 
to be associated with hypercholesterolemia (3,4). 
Homocysteine has been recognised as an independent 
risk factor for atherosclerosis and was linked to the 
pathogenesis of atherosclerosis through induction of 
endothelial apoptosis and dysfunction (5). Despite 
the continuous extensive work investigating drugs 
that can counteract the inflammatory processes in 
atherosclerosis, most of those drugs were found to 
have unavoidable side effects such as myalgia, and 
elevated liver enzymes (1). Honey has been shown 
to exert  modulating activities on serum inflammatory 
marker TNF-α and some other inflammatory cytokines 
(6). Moreover, honey showed lowering effect on serum 
homocysteine level (7). In this work, authors investigated 
Trihoney for its anti-inflammatory effects on the key pro-
atherogenic inflammatory cytokines and homocysteine 
that are implicated in the development and progression 
of atherosclerosis.  Trihoney is a combination of three 
types of honey namely: Trigona, mellifera, and Dorsata. 
This product was made in the Department of Nutrition 
Sciences laboratories, Kulliyyah of Allied Health 
Sciences, International Islamic University Malaysia 
(IIUM). The combination ratio was 45, 15, and 10 of the 
mentioned honey respectively and it was determined 
by Design Expert Version 6.0 software and Response 
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Surface Methodology (RSM) looking for a combination 
formula having the maximum total phenolic content 
(TPC) (unpublished data). Moreover, Trihoney had 
high concentrations of phenolic compounds such as: 
Quercetin, Kaempferol, Rutin, Cathecin, Maleic acid, 
Caffeic acid, Cinnamic acid, Coumaric acid, Gallic acid, 
p-Hydroxybenzoic acid, Salicylic acid, Sinapic acid, 
Vanillic acid, in addition to high antioxidant properties 
were reported through ferric reducing ability of plasma 
analysis (FRAP) and DPPH free radical scavenging 
activity analysis (unpublished data).  Additionally, 
this combination suggested to provide synergistic 
effects between honey types with regard to the anti-
inflammatory and immunomodulatory functions.  
MATERIALS AND METHODS
Trihoney and atorvastatin 
Trihoney was administered to the respective animal 
group by oral route at dose of 0.6g/kg/day. Dose has 
been calculated based on human and rabbit Km factors 
(8).  Atorvastatin 40 mg film-coated tablets (Prague-
Czech) were crushed into fine powder, reconstituted in 
1 mL of distilled water  and given by oral gavage using 
clean syringe (9–11), at a dose of 2mg/kg body weight. 
Preparation of 1% cholesterol diet
Preparation of 1% cholesterol diet was performed as 
follows (10): 40 g of pure cholesterol powder (Nacalai-
Tesque, Kyoto, Japan) was emulsified in 80 mL (=80 
g) of cholesterol free extra virgin coconut oil (product 
of Philippines). The cholesterol emulsion was evenly 
poured over 3880 g of standard rabbit pellets (Perternakan 
Hong Lee Sdn. Bhd, Malaysia). The prepared food (1% 
cholesterol, 2% coconut oil rabbit pellet) then packed in 
zipped bags and kept at temperature of 20-22oC for use.
Animal 
Thirty NZW rabbits of male gender were purchased 
from certified experimental animal supplier (A Sapphire 
Enterprise, Seri Kembangan, Selangor, Malaysia), animal 
weight ranged from 2 to 2.5 kg, and animals age 20 
weeks. Animals were randomly housed in stainless-
steel cages designed for rabbits as a single rabbit per 
cage with free access to water and standard rabbits’ 
pellet in addition to the standard animal care housing 
condition of 12 hours dark/light cycle, temperature 
15-21oC, humidity 45-65%. Procedure of animal 
handling was conducted in accordance with the 
guidelines of Malaysian Code of Practice for the Care 
and Use of Animals for Scientific Purposes (AEPC) (12), 
and the protocol of this experiment was approved by 
the Institutional Animal Care and Use Committee of 
International Islamic University Malaysia (IACUC-IIUM) 
with ID approval (IIUM/IACUC- Approval /2017 (19)).
Experimental study
Thirty male NZW rabbits were grouped into the following 
5 groups: normal diet (C), normal diet with Trihoney dose 
of 0.6g/kg/day (C+H), 1% cholesterol diet (HCD), 1% 
cholesterol diet with 0.6g/kg/day of Trihoney (HCD+H), 
and 1% cholesterol diet with 2mg/kg/day of atorvastatin 
(HCD+At.). Treatment continued for 12 weeks. Blood 
withdrawal has been done from the central ear artery 
(13) after completion of the experimental period.
Blood samples and serum preparation
Blood has been collected from the animals into plain 
tubes, allowed to clot at room temperature for 40 
minutes (14), and then centrifuged (Centrifuge Universal 
320R Hettich, Germany) at 4oC by speed of 3500 rpm, 
for 15 minutes (15,16).  The supernatant sera were 
collected and decanted into 200µL Eppendorf tubes and 
immediately stored at -80oC (Haier Ult Freezer, China) 
until analysed (17,18).  
Enzyme linked immunosorbent assay (ELISA)
Pro-atherogenic inflammatory cytokines: IL-1β and 
TNF-α were determined quantitively using Cusabio 
(Hubei Province-China) ELISA kits for rabbits. Serum 
IL-6 was determined quantitively using Elabscience 
(China) ELISA kit. These assays employed the sandwich-
ELISA principle. Serum homocysteine concentration 
was determined quantitively using homocysteine 
ELISA kit (Cell Biolabs, USA) and this assay employed 
competitive inhibition enzyme immunoassay technique. 
All ELISA procedures were conducted according to the 
manufacturers’ protocols.
Serum glucose analysis
Fasting blood glucose, and fasting insulin were measured 
before commencement of treatment as well as the end 
point of the experiment. Samples were immediately 
analysed by automated analysis machine (Au480 Au 
Analyser-Beckman Coulter, Inc.).
Statistical analysis
Statistical Package for Social Sciences (SPSS version 
21 Chicago, Illinois, USA) software was used for data 
processing.   Data were expressed as mean (M) and 
standard deviation (SD) and analysed by one-way 
analysis of variance (ANOVA). One-way ANOVA 
followed by Post Hoc test used for determination of 
significant differences between means of two or more 
independent groups. Statistically significance considered 
at p< 0.05. 
 
RESULTS  
Trihoney supresses pro-atherogenic inflammatory 
cytokines 
Tremendous significant increase in serum IL-1β was 
seen in HCD group following 12 weeks treatment with 
1% cholesterol diet (Table I). The HCD group showed 
significant (p<0.001) increase in serum IL-1β seen 
when compared to both C and C+H groups. On the 
other hand, Trihoney treated group HCD+H showed 
significantly (p<0.05) lower serum level of IL-1β when 
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serum homocysteine concentration comparable to the 
control groups but significantly (p<0.05) lower than that 
of the HCD group (Table III).
Table I:  Effects of 1% cholesterol diet and Trihoney on serum 
pro-atherogenic inflammatory cytokines
Group IL-1β (pg/mL) IL-6 (pg/mL) TNF-α (pg/mL)
C 85.99±5.84 6.37±0.68 15.09±0.32
C+H 83.08±10.42 6.56±0.34 14.20±0.21





HCD+At. 85.99±5.84c*** 6.95±2.00 13.90±0.18c**
Values are mean ± standard deviation (SD) of the mean. The results of all experiment groups 
were analysed using one-way analysis of variance (ANOVA), followed by LSD Post Hoc test. 
Mean difference is considered significant at (p<0.05). a= significant different from C group, 
b= significant different from C+H group, c= significant different from HCD group. [*= p<0.05, 
**=p<0.01, ***=p<0.001].
compared to the HCD group. Animal group HCD+At. 
which received atorvastatin exhibited serum IL-1β result 
very close to that of the C and C+H groups, in addition 
to a very significant (p<0.001) reduction in serum IL-
1β compared to the HCD group. Serum IL-1β level in 
Trihoney treated group was comparable to that of the 
HCD+At. group. Very significant (p<0.001) positive 
correlation found between serum level of IL-β and 
aortic lesion area percentage. Likewise, serum IL-1β 
had significant (p<0.01 and p<0.05) positive correlation 
with serum total cholesterol (TC) and serum low-density 
lipoprotein cholesterol (LDL-c) levels respectively 
(Table II). Serum IL-6 level was higher in the HCD group 
compared to all other experimental groups. Trihoney 
treated group HCD+H showed significant (p<0.05) 
reduction in serum IL-6 level in comparison to the HCD 
group. The HCD+At. group had a lower serum IL-6 level 
in comparison to the HCD group even it was statistically 
not significant but it was very close to that of the control 
groups. The HCD group demonstrated a significant 
(p<0.05) elevation of serum TNF-α compared to the C 
group. Group supplemented with Trihoney exhibited 
serum TNF-α significantly (p<0.001) lower than that 
of the HCD group. Atherogenic group treated with 
atorvastatin showed significant (p<0.01) lower serum 
TNF-α level compared to HCD group.    
Trihoney is a cardiovascular protective against 
hyperhomocysteinemia 
The 1% cholesterol diet group had serum homocysteine 
level comparable to that of the control groups without any 
significant difference despite little increase in the mean 
value. Atherogenic group supplemented with Trihoney 
showed serum homocysteine level comparable to that of 
the control groups. Likewise, HCD+At. group exhibited 
Table II: Correlation between serum interleukin-1β (IL-1β), and se-
rum total cholesterol (TC), serum low-density lipoprotein cholesterol 










Values are the Pearson correlation coefficient (r) between interleukin-1β (IL-1β), lipid profile, 
and aortic lesion area percentage (%) of the all experimental groups. [*= p<0.05, **=p<0.01, 
***=p<0.001 Sig. (2-tailed)].
Table III: Effect of Trihoney and 1% cholesterol diet on serum ho-
mocysteine






Values are mean ± standard deviation (SD) of the mean. The results of all experiment groups 
were analysed using one-way analysis of variance (ANOVA), followed by LSD Post Hoc test. 
Mean difference is considered significant at (p<0.05). a= significant different from C group, 
b= significant different from C+H group, c= significant different from HCD group. [*= p<0.05, 
**=p<0.01, ***=p<0.001].
Table IV: Effect of Trihoney on serum glucose 






Values are mean ± standard deviation (SD) of the mean. The results of all experiment groups 
were analysed using one-way analysis of variance (ANOVA), followed by LSD Post Hoc test. 
Mean difference is considered significant at (p<0.05).  
Trihoney maintains normoglycemic status
Analysis of fasting serum glucose of all experimental 
groups showed no significant difference (p>0.05) after 
12 weeks of treatment (Table IV).
DISCUSSION
Interleukin-1β and IL-6 are pro-atherogenic cytokines 
secreted by macrophages, smooth muscle cells (SMCs), 
and lymphocytes (2). The role of  these cytokines 
in atherosclerosis is implicated in atherogenesis, 
endothelial adhesiveness and in induction of 
inflammatory markers (19). Among all cytokines , IL-1β 
has the most crucial role in inflammatory diseases (20). 
Interleukin-1β  induces synthesis of IL-6 and TNF-α, and 
stimulates endothelial adherence of leukocytes through 
upregulation of intercellular adhesion molecule-1 
(ICAM-1) (21). Interleukin-6 stimulates proliferation 
and differentiation of B and T lymphocytes, regulates 
the expression vascular endothelial growth factor 
(VEGF) (22), and contributes to atherosclerotic plaque 
development and plaque destabilisation (23).  High 
circulating levels of  TNF-α was found to have an 
association with the extent of atherosclerotic lesions in 
patients having acute coronary syndrome (ACS), and 
based on this role, TNF-α has been nominated as a pro-
atherogenic cytokine (2,23). 
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In our study, feeding NZW rabbits for 12 weeks with 
1% cholesterol diet resulted in significant elevation 
of serum IL-1β, IL-6 and TNF-α. These findings are 
supported by other hypercholesterolemic animal 
models that investigated the role of these pro-
atherogenic inflammatory cytokines in the setting of 
hypercholesterolemia (3,24–27). In this experiment, we 
reported that Trihoney caused significant reduction in 
the serum level of IL-1β in hypercholesterolemic rabbits. 
This interesting finding may indicate the protective 
function of Trihoney against atherosclerosis progression. 
Moreover, this result indicated the anti-inflammatory 
property of Trihoney. Interleukin-1β is described as the 
master cytokine of inflammation in a broad spectrum 
of diseases including ACS (28), thus reducing its serum 
level in hypercholesterolemic model by using Trihoney 
may suggest this natural product as promising adjuvant 
therapeutic option to prevent or for minimise the 
inflammatory cascade in atherosclerosis.  
Our results showed significant positive correlation 
between serum IL-1β level and the percentage of aortic 
atherosclerotic plaques, and this finding may indicate 
the pathogenic importance of IL-1β for the development 
of atherosclerotic plaques. Experimental studies showed 
practical evidence for the direct relationship between 
IL-1β and the atherosclerotic plaques progression. 
Inhibition of IL-1β was found to be associated with 
inhibition of atherosclerotic plaque formation, whereas 
increased IL-1β activity resulted in lesion progression 
(29).  We reported positive correlation between serum 
IL-1β, serum TC and LDL-c. This correlation is supported 
by the natural history of pathogenesis of atherosclerosis 
following hypercholesterolemia (30). We demonstrated 
significant reduction in serum level of IL-6 when 
Trihoney was supplemented simultaneously with the 
atherogenic diet. This finding strongly supported the 
anti-inflammatory and the immune modulating role 
of Trihoney in the case of hypercholesterolemia and 
suggesting its protective function against the process of 
atherosclerosis. 
Researchers work extensively to find medicines that are 
able to block inflammatory process mastered by these 
pro-atherogenic cytokines. Some of the medicinal drugs 
are approved and some are under clinical trials (28, 29). 
Despite the evidence of medical improvement in some 
of the examined inflammatory diseases, investigated 
drugs are associated with some serious side effects (29). 
In this investigation, we showed significant reduction 
in serum TNF-α in Trihoney supplemented group. The 
potential of Trihoney towards reduction of TNF-α in this 
experiment was very comparable to or to some extent 
more marked than atorvastatin. The reported reduction 
of pro-atherogenic inflammatory cytokines in our study 
is in line with investigation conducted by Hussein et al. 
(2012) who reported reduction in IL-6 and TNF-α, both 
in serum and skin tissue following treatment with the 
Malaysian Gelam honey in rat model (31). Clinical trial 
study involving daily oral supplementation with natural 
honey for 10 weeks showed decrease in inflammatory 
cytokines IL-6 and TNF-α (32), which is in agreement 
with our findings. One more interesting finding about 
honey and cytokines in wounds is that, honey can 
induce and can inhibit cytokine production depending 
on wound condition (33).  In vitro studies showed that 
honey had stimulatory effect on cytokine production 
(34, 35).  In a recent randomised controlled trial study 
using Malaysian Tualang (Dorsata) honey supplemented 
to chronic smokers for 12 weeks in order to examine 
its effect on inflammatory cytokines, authors reported 
that honey causes opposite effects on high sensitivity 
C-reactive protein (hs-CRP) and TNF-α. Smokers who 
received honey had high TNF-α and low hs-CRP post-
intervention compared to pre-intervention and authors 
attributed these conflicting effects to the nonconclusive 
effects of Tualang honey on those two inflammatory 
markers (36).  The anti-inflammatory effect of Dorsata 
honey against hs-CRP most likely attributed to the 
phenolic compounds present in honey (36).  
The possible anti-inflammatory mechanisms exerted 
by honey may operate through the nuclear factor 
kappa B (NF-kB) which has been implicated as a key 
inflammatory factor. Gelam honey has been reported to 
inhibit the nuclear translocation and activation of NF-
kB and subsequently caused reduction in expression 
of proinflammatory mediators tumour necrosis factor-
alpha (TNF-α) and cyclooxygenase-2 (COX-2), thereby 
reducing the inflammation (37). Natural honey has been 
shown to reduce serum levels of prostaglandins (PGE2, 
PGF2α, and thromboxane B2), and this inhibitory 
effect found to increase with time, the site of action 
may involve COX-2, COX-1, or both (38). The  anti-
inflammatory effects of Trihoney can also be attributed 
to nitric oxide, vitamin E, prostaglandins, and phenolic 
compounds  present in this mixture (39). 
In our study, we used atorvastatin as a positive control 
because it is a well-known anti-atherosclerotic agent 
(40) with protective and therapeutic functions (41). The 
treatment group receiving atorvastatin had reduced 
serum levels of IL-1β, IL-6 and TNF-α. Atorvastatin 
treated group showed very close serum IL-1β to 
that of the control groups C and C+H. This finding 
indicated the anti-inflammatory effect of atorvastatin in 
hypercholesterolemia induced atherosclerosis. In line 
with our results,  Loppnow et al. (2011) demonstrated 
an in vitro study of the inhibitory function of atorvastatin 
on the release of IL-6 in (SMC)/human mononuclear 
cell (MNC) coculture atherosclerotic model (42).  This 
inhibitory effect of statins on IL-6 was also described by 
in vivo study looking for anti-inflammatory functions 
of statins (43). In agreement with our findings, in vitro 
study has demonstrated the anti-inflammatory ability of 
atorvastatin to downregulate IL-1β, IL-6, and TNF-α (42). 
Despite that, the effects of statins on these cytokines 
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Interestingly, atorvastatin treated group in this study 
showed the lowest serum homocysteine level compared 
to all other treated and untreated experimental groups. No 
significant difference was reported between atorvastatin 
treated group and the control and HCD+H groups. On 
the other hand, this group had serum homocysteine 
level significantly (p<0.05) lower than the HCD group. 
This report is not in line with Bolayirli et al. (2007) 
who reported that atorvastatin unexpectedly increased 
serum homocysteine level in hypercholesterolemic 
rabbits (13). Our results showed that Trihoney may be 
comparable to atorvastatin in the setting of protection 
against hyperhomocysteinemia. 
As far as serum glucose is concerned, treatment with 
Trihoney for 12 weeks had not induced disturbance 
of blood glucose, in other word Trihoney is not 
diabetogenic agent.
CONCLUSION
Trihoney exhibited anti-inflammatory effects by 
inducing significant reduction of serum pro-atherogenic 
inflammatory cytokines: IL-1β, IL-6 and TNF-α. Trihoney 
had neutral effect on serum homocysteine level and 
maintained a normoglycemic status. Trihoney has the 
potential cardioprotective and anti-atherosclerotic 
effects and may be suggested as an adjuvant remedy for 
management of atherosclerotic vascular diseases. 
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